The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression
This review (2023) focuses on the role of the ego in psychedelic-assisted psychotherapy (PAT), particularly through a psychodynamic lens. It argues that psychedelics induce regressed states of the ego, allowing for emotional integration of early life events that have shaped a person's character and defence mechanisms. The paper posits that for lasting change, PAT must target the characterological core of the ego's habitual patterns, and it suggests that this psycholytic approach is compatible with other forms of PAT like third-wave cognitive behavioural approaches (CBT/ACT).
Authors
- Hannes Kettner
- Laura Kartner
Published
Abstract
The ego is one of the most central psychological constructs in psychedelic research and a key factor in psychotherapy, including psychedelic-assisted forms of psychotherapy. Despite its centrality, the ego-construct remains ambiguous in the psychedelic literature. Therefore, we here review the theoretical background of the ego-construct with focus on its psychodynamic conceptualization. We discuss major functions of the ego including ego boundaries, defenses, and synthesis, and evaluate the role of the ego in psychedelic drug action. According to the psycholytic paradigm, psychedelics are capable of inducing regressed states of the ego that are less protected by the ego’s usual defensive apparatus. In such states, core early life conflicts may emerge that have led to maladaptive ego patterns. We use the psychodynamic term character in this paper as a potential site of change and rearrangement; character being the chronic and habitual patterns the ego utilizes to adapt to the everyday challenges of life, including a preferred set of defenses. We argue that in order for psychedelic-assisted therapy to successfully induce lasting changes to the ego’s habitual patterns, it must psycholytically permeate the characterological core of the habits. The primary working principle of psycholytic therapy therefore is not the state of transient ego regression alone, but rather the regressively favored emotional integration of those early life events that have shaped the foundation, development, and/or rigidification of a person’s character - including his or her defense apparatus. Aiming for increased flexibility of habitual ego patterns, the psycholytic approach is generally compatible with other forms of psychedelic-assisted therapy, such as third wave cognitive behavioral approaches.
Research Summary of 'The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression'
Introduction
Buchborn and colleagues frame the ego as a central but ambiguously defined construct in psychedelic research and psychotherapy. They note that while phenomena such as ego dissolution are widely discussed in the psychedelic literature, the original psychodynamic formulation of the ego has received little sustained attention. Contemporary measures in the field tend to focus on phenomenology (subjective experience) rather than on the ego's functional roles, and the psychodynamic perspective has been comparatively sidelined by other frameworks such as cognitive behavioural approaches and the broader ‘‘self’’ construct. This review aims to reintroduce and synthesise psychodynamic concepts of the ego for the psychedelic literature. The authors set out to (1) describe core ego functions from drive and ego psychology (including ego boundaries, defenses, synthesis and the mental representation of the self), (2) evaluate evidence that psychedelics transiently disrupt these functions—producing regression and loosening of defenses—and (3) explore therapeutic implications, especially from the psycholytic tradition in which repeated lower-dose sessions aim to reach and remodel character (habitual ego patterns). They propose that for psychedelic-assisted therapy to produce sustained change it must psycholytically access and integrate the characterological roots of maladaptive ego patterns within a robust therapeutic alliance.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Topic
- Authors
- APA Citation
Buchborn, T., Kettner, H. S., Kärtner, L., & Meinhardt, M. W. (2023). The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression. Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1232459
References (52)
Papers cited by this study that are also in Blossom
Barba, T., Buehler, S., Kettner, H. et al. · BJPsych Open (2022)
Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2018)
Brennan, W., Jackson, M. A., MacLean, K. A. · Journal of Humanistic Psychology (2021)
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Show all 52 referencesShow fewer
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Deane, G. · Neuroscience of Consciousness (2021)
Dupuis, D. · Frontiers in Psychology (2021)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)
Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)
Gukasyan, N., Nayak, S. · Preprints (2020)
Guss, J. · Psychoanalytic Dialogues (2022)
Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Ledwos, N., Rodas, J. D., Husain, M. I. et al. · Journal of Psychopharmacology (2022)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Marek, G. J. · Current Topics in Behavioral Neurosciences (2018)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Mertens, L. J., Preller, K. H. · Pharmacopsychiatry (2021)
Millière, R. · Frontiers in Human Neuroscience (2017)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Passie, T., Guss, J., Kraehenmann, R. · Frontiers in Psychiatry (2022)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Ramachandran, V., Chunharas, C., Marcus, Z. et al. · Neurocase (2018)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Human Brain Mapping (2020)
Spriggs, M. J., Murphy-Beiner, A., Murphy, R. et al. · Psychological Medicine (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)
Cited By (3)
Papers in Blossom that reference this study
Brown, R. E., Lissemore, J. I., Shinozuka, K. F. et al. · Journal of Affective Disorders (2026)
Kettner, H., Roseman, L., Gazzaley, A. et al. · The American Journal of Geriatric Psychiatry (2024)
Tap, S. C. · Addiction Biology (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.